UK measles and rubella elimination indicators and status
Updated 25 October 2022
UK measles and rubella elimination
Measles and rubella can be eliminated and congenital rubella infections prevented by achieving high uptake of the combined measles, mumps and rubella (MMR) vaccine in national childhood immunisation programmes. All Member States of the World Health Organization (WHO) European Region have a longstanding commitment to eliminating measles and rubella and this is a core goal of the European Vaccine Action Plan 2015 to 2020. In the UK the MMR vaccine is offered to all children at 1 year of age, with a second dose given at 3 years and 4 months.
UK Health Security Agency is responsible for collating and submitting evidence every year, on behalf of the devolved administrations (England, Wales, Scotland and Northern Ireland), to the UK national verification committee (NVC) and the WHO Regional Verification Commission for Measles and Rubella Elimination (RVC) for review and evaluation on an annual basis.
The elimination verification process is based on evidence documented by each Member State to show whether interruption of endemic transmission of measles and/or rubella at national level has been achieved and, if not, that a national plan has been developed to address this.
The following essential criteria are required to verify elimination of measles and rubella in the UK:
- the absence of endemic measles and rubella cases for a period of at least 12 months from the last known case, due to complete interruption of endemic virus transmission
- the presence of a high-quality surveillance system that is sensitive and specific enough to detect, confirm and classify all suspected cases
- genotyping evidence that supports the interruption of endemic transmission
The WHO confirmed that the UK achieved elimination status for rubella in 2016. After briefly achieving measles elimination in 2016 and 2017, since 2018 the UK has re-established transmission of measles virus. See Tables 1 and 2.
Table1. Measles elimination indicators and status, 2010 to 2021, UK
Year | MMR vaccine coverage 1st dose (%) | MMR vaccine coverage 2nd dose (%) | Measles cases [footnote 1] | Incidence per million | WHO status |
2010 | 91.9 | 83.6 | 407 | 6.09 | endemic transmission[footnote 2] |
2011 | 93.1 | 85 | 1112 | 15.99 | endemic transmission[footnote 2] |
2012 | 94.2 | 86.5 | 2052 | 32.15 | endemic transmission[footnote 2] |
2013 | 94.7 | 88.9 | 1853 | 28.91 | endemic transmission[footnote 2] |
2014 | 94.6 | 89 | 96 | 1.5 | interrupted endemic transmission[footnote 3] |
2015 | 94.8 | 89.3 | 90 | 1.1 | interrupted endemic transmission[footnote 3] |
2016 | 95.1 | 88.9 | 562 | 10.4 | eliminated |
2017 | 95.3 | 88.2 | 349 | 4.4 | eliminated |
2018 | 95.2 | 87.8 | 1250 | 17.1 | re-established transmission of measles virus[footnote 2] |
2019 | 94.8 | 87.2 | 1117 | 15.3 | re-established transmission of measles virus[footnote 2] |
2020 | 94.8 | 87.5 | 95 | 1.3 | re-established transmission of measles virus[footnote 2] |
2021 | 94.6 | 87.4 | 2 | 0 | pending |
This measles blog by Dr. Vanessa Saliba explains why are we still seeing measles cases in the UK. Measles elimination can only be achieved and maintained by reaching 95% coverage with 2 doses of the MMR vaccine in children and by using all opportunities to catch up older children and adults who missed out when they were younger.
Table 2. Rubella elimination indicators and status 2010 to 2021, UK
Year | MMR vaccine coverage 1st dose (%) | MMR vaccine coverage 2nd dose (%) | Rubella cases [footnote 4] | Incidence per million | WHO status |
2010 | 91.9 | 83.6 | 12 | 0.14 | interrupted endemic transmission[footnote 3]] |
2011 | 93.1 | 85 | 6 | 0.11 | interrupted endemic transmission[footnote 3] |
2012 | 94.2 | 86.5 | 61 | 0.75 | endemic transmission[footnote 2] |
2013 | 94.7 | 88.9 | 7 | 0.11 | interrupted endemic transmission[footnote 3] |
2014 | 94.6 | 89 | 1 | 0.02 | interrupted endemic transmission[footnote 3] |
2015 | 94.8 | 89.3 | 2 | 0.02 | eliminated |
2016 | 95.1 | 88.9 | 2 | 0.02 | eliminated |
2017 | 95.3 | 88.2 | 10 | 0.1 | eliminated |
2018 | 95.2 | 87.8 | 3 | 0.02 | eliminated |
2019 | 94.8 | 87.2 | 3 | 0.02 | eliminated |
2020 | 94.8 | 87.5 | 0 | 0 | eliminated |
2021 | 94.6 | 87.4 | 0 | 0 | pending |
Table 3. WHO indicators and targets for measuring performance of measles surveillance 2010 to 2021
Year | Timeliness (%) [footnote 5] | Completeness of reporting (%) [footnote 6] | Rate of laboratory investigations (%) [footnote 7] | Rate of discarded cases per 100,000 population [footnote 8] | Representativeness of reporting discarded cases [footnote 9] | Viral detection [footnote 10] | Origin of infection identified [footnote 11] | Timeliness of investigation [footnote 12] |
2010 | 83 [footnote 13] | 100 | 122 [footnote 14] | 5.4 | 100 | |||
2011 | 73 [footnote 13] | 100 | 105 [footnote 14] | 5.8 | 100 | |||
2012 | 70 [footnote 13] | 100 | 111 [footnote 14] | 8.5 | 100 | |||
2013 | 100 | 100 | >89 UK [footnote 15] | 10.3 UK | 72 | 100 | 100 | >89 [footnote 15] |
2014 | 100 | 100 | 73 England; 83 Wales; 94 N Ireland; NK Scotland | 4.9 England; 4.8 Wales; 0.8 N Ireland; 0.8 Scotland | 50 | 100 | 100 | 100 |
2015 | 100 | 100 | 73 England; 81 Wales; 56 N Ireland; NK Scotland | 3.1 England; 2.7 Wales; 0.9 N Ireland; NK Scotland | 50 | 100 in clusters; 50 in sporadic cases | 100 | 100 |
2016 | 100 | 100 | 78 England; 79 Wales; 92 N Ireland; NK Scotland | 3.7 England; 3.6 Wales; 2.9 N Ireland; NK Scotland | 66 | 91% clusters; 66% sporadic cases | 100 | 100 |
2017 | 100 | 100 | 98.3 | 4.4 England; 1.9 Scotland; 2 N Ireland; 5.2 Wales | 92 | 96.1 | 99 | 100 |
2018 | 100 | 100 | 94.4 | 5.8 England; 1.6 N Ireland; 1.3 Scotland; 10 Wales | 83.3 | 98.8 | 100 | 100 |
2019 | 100 | 100 | 93.9 | 5.4 England; 4.6 N Ireland; 14.9 Scotland; 5.9 Wales | 100 | 86 | 96.3 | 85.4 |
2020 | 100 | 100 | 98.7 | 2.8 England; 1.6 N Ireland; 4.4 Scotland; 1.5 Wales | 25 | 100 | 100 | 100 |
2021 | 100 | 100 | 99.9 | 1.7 England; 0.4 N Ireland; 3.8 Scotland; 1.7 Wales | 33.3 | 100 | 100 | 100 |
Table 4. WHO indicators and targets for measuring performance of rubella surveillance 2010 to 2021
Year | Timeliness (%) [footnote 5] | Completeness of reporting (%) [footnote 6] | Rate of laboratory investigations (%) [footnote 7] | Rate of discarded cases per 100,000 population [footnote 8] | Representativeness of reporting discarded cases [footnote 9] | Viral detection [footnote 10] | Origin of infection identified [footnote 11] | Timeliness of investigation [footnote 12] |
2010 | 61 [footnote 13] | 100 | 105 [footnote 14] | 1.2 | 100 | |||
2011 | 57 [footnote 13] | 100 | 93 [footnote 14] | 1.1 | 100 | |||
2012 | 69 [footnote 13] | 100 | 162 [footnote 14] | 2.4 | 100 | |||
2013 | 100 | 100 | 124 [footnote 16] | 1.6 | <80 [footnote 17] | 0 | 100 | >84 [footnote 15] |
2014 | 100 | 100 | 79 England; 94 Wales; 100 N Ireland; NK Scotland | 1.4 England; 0.1 Wales; 0.1 N Ireland; 0.05 Scotland | 0 | N/A | 100 | 100 |
2015 | 100 | 100 | 74 England; 65 Wales; 60 N Ireland; NK Scotland | 2.4 England; 0.6 Wales; 0.2 N Ireland; NK Scotland | 25 | 35 | 100 | 100 |
2016 | 100 | 100 | 64 England; 63 Wales; 0 N Ireland; NK Scotland | 3.4 England; 0.6 Wales; 0 N Ireland; NK Scotland | 41 | 0 | 100 | 100 |
2017 | 100 | 100 | 99.6 | 2.4 England; 0.2 Scotland; 0.3 N Ireland; 0.4 Wales | 50 | N/A | 60 | 100 |
2018 | 100 | 100 | 100 | 3.1 England; 0.7 N Ireland; 0.6 Scotland; 3.1 Wales | 75 | N/A | 100 | 100 |
2019 | 100 | 100 | 100 | 1.6 England; 0.4 N Ireland; 1.2 Scotland; 1.8 Wales | 33 | 0 | 100 | 87 |
2020 | 100 | 100 | 100 | 1.4 England; 0.4 N Ireland; 0.4 Scotland; 1.1 Wales | 8.3 | N/A | N/A | 100 |
2021 | 100 | 100 | 100 | 1.0 England; 0.2 N Ireland; 0.5 Scotland; 0.4 Wales | 0 | N/A | N/A | 100 |
-
a suspected case that meets the laboratory/epidemiological/clinical criteria for measles (definitions have changed over time) ↩
-
continuous transmission of indigenous or imported measles or rubella virus that persists for a period of 12 months or more in a defined geographical area ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
the absence of endemic measles or rubella cases in a defined geographical area for a period of at least 12 months, in the presence of a well-performing surveillance system. Regional elimination can be declared after 36 or more months of the absence of endemic measles or rubella in all Member States ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
a suspected case that meets the laboratory/epidemiological/clinical criteria for rubella (definitions have changed over time) ↩
-
percentage of measles or rubella routine surveillance reports submitted to the national level by the deadline ↩ ↩2
-
percentage of measles or rubella routine surveillance reports submitted to the national level ↩ ↩2
-
percentage of cases suspected for measles or rubella with adequate specimens collected and tested in a WHO accredited or proficient laboratory ↩ ↩2
-
the rate of suspected measles or rubella cases investigated and discarded as non-measles or non-rubella cases using laboratory testing in a proficient laboratory and/or epidemiological linkage to another confirmed disease ↩ ↩2
-
percentage of subnational administrative territories (e.g. at the province level or its administrative equivalent) reporting the rate of discarded cases at least 2 per 100 000 population per year ↩ ↩2
-
percentage of laboratory-confirmed chains of transmission of measles or rubella with samples adequate for viral detection collected and tested in an accredited laboratory ↩ ↩2
-
percentage of measles or rubella cases for which the origin of infection (imported, import-related or endemic) has been identified ↩ ↩2
-
percentage of suspected measles or rubella cases with an adequate investigation initiated within 48 hours of notification ↩ ↩2
-
there are percentages of IgM results reported out within 7 days of receipt of specimen. If public health action is required specimens are tested and reported out within 1 working day. ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
this is based on the number of specimens tested / cases reported in England (2010 to 2012) and Wales (2012 only) ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
estimate based on England and N Ireland records where data available; (likely to be an underestimate) ↩ ↩2 ↩3
-
estimate based on number of cases reported to local teams (England) and number of suspected cases tested at proficient lab ↩
-
not meaningful for UK as not meeting the 2 per 100,000 rate at national level ↩